front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |review |
New methods of control are being proposed, and include, among many others:
*Water management, “flushing” the larvae with strong currents in the quiet ponds and streams, removing plants which serve as refuge, or letting rice paddies dry for short periods to kill the larvae. |
* Expanded polystyrene spherules, which cover the surface of ponds and smother the larvae.
* Insect repellents, either chemical or through ultrasound, applied on people or on curtains or bednets. Pyrethroid-impregnated bednets have definitively shown their worth in many areas.
* Malarial vaccines -
after having been developed experimentally and shown
to work in animals, tests in humans are being performed specially with
SPf66, produced by Dr. Manuel Elkin Patarroyo. Present vaccines are still
not effective enough.
Engers and Godal (Parasitology Today, 14: 56-64, 1988) state:
Based on the recent experiences gained in various field trials with SPf66,
it is clear that many points remain to be developed in this domain (testing
of malaria vaccine candidates), especially in the area of protocol design
and definition of relevant, achievable endpoints. Nevertheless, on a global
scale, considerable experience has accumulated with respect to malaria
vaccine testing, with ~20 PhaseI/II clinical trials with various P.
falciparum pre-erythrocytic vaccine candidates having been conducted to date
in the USA, Kenya and Thailand. In addition, at least six asexual-stage and
multicomponent vaccine candidates have been tested or are currently
undergoing Pase I/II trials in the USA, Switzerland, Burkina Faso, Nigeria,
Sri Lanka, Australia and Papua New Guinea. And, finally, SPf66 has been
tested in clinical and field trials in Clombia, Venezuela, ecuador, Brazil,
USA, Tanzania, The Gambia and Thailand.